These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11069211)

  • 1. Clinical pharmacokinetics of ropinirole.
    Kaye CM; Nicholls B
    Clin Pharmacokinet; 2000 Oct; 39(4):243-54. PubMed ID: 11069211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
    Thalamas C; Taylor A; Brefel-Courbon C; Eagle S; Fitzpatrick K; Rascol O
    Eur J Clin Pharmacol; 1999 Jun; 55(4):299-303. PubMed ID: 10424323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease.
    Hattori N; Hasegawa K; Sakamoto T
    J Clin Pharm Ther; 2012 Oct; 37(5):571-7. PubMed ID: 22390368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of ropinirole in animals and man.
    Ramji JV; Keogh JP; Blake TJ; Broom C; Chenery RJ; Citerone DR; Lewis VA; Taylor AC; Yeulet SE
    Xenobiotica; 1999 Mar; 29(3):311-25. PubMed ID: 10219970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
    Taylor AC; Beerahee A; Citerone DR; Cyronak MJ; Leigh TJ; Fitzpatrick KL; Lopez-Gil A; Vakil SD; Burns E; Lennox G
    Pharmacotherapy; 1999 Feb; 19(2):150-6. PubMed ID: 10030765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ropinirole, a non-ergoline dopamine agonist.
    Jost WH; Angersbach D
    CNS Drug Rev; 2005; 11(3):253-72. PubMed ID: 16389293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
    Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
    Brefel C; Thalamas C; Rayet S; Lopez-Gil A; Fitzpatrick K; Bullman S; Citerone DR; Taylor AC; Montastruc JL; Rascol O
    Br J Clin Pharmacol; 1998 Apr; 45(4):412-5. PubMed ID: 9578193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ropinirole in the treatment of restless legs syndrome.
    Kakar RS; Kushida CA
    Expert Rev Neurother; 2005 Jan; 5(1):35-42. PubMed ID: 15853472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
    Fleishaker JC
    Clin Pharmacokinet; 2000 Dec; 39(6):413-27. PubMed ID: 11192474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.
    Onofrj M; Bonanni L; De Angelis MV; Anzellotti F; Ciccocioppo F; Thomas A
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S85-92. PubMed ID: 20123565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects of ropinirole in patients with idiopathic Parkinson's disease.
    Titlic M; Tonkic A; Jukic I; Lusic I; Dikanovic M
    Bratisl Lek Listy; 2008; 109(6):273-5. PubMed ID: 18700440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
    Tompson DJ; Vearer D
    Clin Ther; 2007 Dec; 29(12):2654-66. PubMed ID: 18201581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.